Single dose of AZD7442 effectively prevents COVID-19
Apr 22, 2022
A relative risk reduction of 82.8% was seen in symptomatic COVID-19 at extended follow-up of a median of six months.
Assisted living providers prohibited from denying employee COVID vaccine exemption requests
By
Kimberly Bonvissuto
Apr 22, 2022
An amendment to an existing state law expands protections for employees subject to employer COVID-19 vaccine mandates, further complicating the pandemic landscape for assisted living providers in Tennessee.
Early effectiveness assessed for fourth dose of BNT162b2 vaccine
Apr 21, 2022
The difference in absolute risk for three versus four doses was 180.1 and 68.8 cases per 100,000 for COVID-19-related hospitalization and severe COVID-19.
Overall risk of myopericarditis low after COVID-19 vaccine
Apr 12, 2022
The overall incidence of myopericarditis does not differ significantly for those receiving COVID-19 vaccines versus non-COVID-19 vaccines.
Fourth dose of BNT162b2 offers protection against severe COVID-19
Apr 08, 2022
Protection against COVID-19 did not wane in six weeks after receipt of fourth dose of the Pfizer–BioNTech vaccine; protection against the infection waned.
‘Natural immunity’ now satisfies employer vaccine mandates in Utah
By
Kimberly Bonvissuto
Mar 30, 2022
Natural immunity to COVID-19 infection could allow Utah senior living and other workers to sidestep workplace vaccine mandates.
Low COVID-19 vaccination rates among Medicaid beneficiaries cause for concern: senators
By
Kimberly Bonvissuto
Mar 29, 2022
Concern over lagging vaccination rates among Medicaid beneficiaries has prompted two Democratic leaders to request a study from the Government Accountability Office on potential barriers to vaccination.
Fourth mRNA COVID-19 vaccine immunogenic, safe
Mar 24, 2022
Vaccine efficacy 30% for BNT162b2(Pfizer) and 11 percent for mRNA-1273 (Moderna) against any SARS-CoV-2 infection.
Risk for shoulder conditions small after vaccination in deltoid muscle
Mar 21, 2022
The incidence of shoulder conditions per 10,000 vaccinations was 1.22 for adults (age 18 years or older) and 0.05 for children (age 3 to 17 years).
Moderna asks FDA to approve second booster for all adults
Mar 18, 2022
The Moderna request covers all adults to give federal health officials the freedom to determine who should get a second booster.